Corcept Therapeutics (NASDAQ: CORT) — Perfil da empresa, notícias e dados financeiros
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs that modulate the effects of cortisol.
Corcept Therapeutics
Corcept Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs that modulate the effects of cortisol. High cortisol activity is linked to various severe endocrinologic, oncologic, metabolic, and neurological disorders. The company's approved product, Korlym (mifepristone), is an oral cortisol receptor blocker prescribed for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Corcept also develops a pipeline of proprietary selective cortisol modulators targeting clinical indications in Cushing's syndrome, solid tumors, liver disease, and amyotrophic lateral sclerosis.
Resumo
Operações
Produtos e/ou serviços de Corcept Therapeutics
- Endocrinology Treatments: Provides oral cortisol receptor antagonist tablets prescribed to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing syndrome who have type 2 diabetes or glucose intolerance.
- Endocrine Disease Clinical Development: Advances selective glucocorticoid receptor antagonists through pivotal Phase 3 trials for Cushing syndrome and hypercortisolism, designed to provide cortisol modulation without activity at progesterone or androgen receptors.
- Oncologic Cortisol Modulation: Evaluates selective cortisol modulators in combination with chemotherapy regimens in Phase 2 and Phase 3 trials to overcome anti-apoptotic resistance mechanisms in platinum-resistant ovarian cancer and other solid tumors.
- Metabolic Health Therapeutics: Researches small-molecule glucocorticoid receptor antagonists in clinical development for metabolic dysfunction-associated steatohepatitis and for mitigating weight gain associated with second-generation antipsychotic medication use.
- Neurology Disease Programs: Investigates selective cortisol modulators in Phase 2 clinical trials for amyotrophic lateral sclerosis and related neurodegenerative disorders, targeting pathways where elevated glucocorticoid activity accelerates disease progression.
- Selective Compound Discovery: Discovers and synthesizes proprietary small molecules that target cortisol binding at glucocorticoid receptors, building an intellectual property portfolio of distinct drug candidates across endocrine, metabolic, and oncologic indications.
equipe executiva do Corcept Therapeutics
- Joseph K. BelanoffCo-Founder, President, CEO & Director
- Atabak MokariCFO & Treasurer
- William GuyerChief Development Officer
- Gary Charles RobbChief Business Officer & Secretary
- Joseph Douglas LyonChief Technology & Accounting Officer
- Hazel HuntChief Scientific Officer
- Amy FloodChief Human Resources & Communications Officer
- Monica TelladoPresident of Emerging Markets
- Roberto W. VieiraPresident of Oncology
- Justin GunnPresident of Endocrinology
Últimas notícias sobre a Corcept Therapeutics
Principais indicadores financeiros
Resultados divulgados pela Corcept Therapeutics, em USD.
- Cap. de mercado
- 9,3 bi
- Receita (TTM)
- 830,8 mi
- P/L
- 196.1
- LPA (diluído, TTM)
- 0.4
- Dividend yield
- —
- Margem de lucro
- 6.6%
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 761,4 mi | 44,8 mi | 99,7 mi | |
| 675 mi | 137 mi | 139,7 mi | |
| 482,4 mi | 107,3 mi | 106,1 mi | |
| 401,9 mi | 112,6 mi | 101,4 mi |